Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
NCT03643133Phase 2Active, not recruiting
- Sponsor
- Unicancer
- Start
- Oct 2018
- Primary completion
- Sep 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mifamurtide in osteosarcoma (OS) (2 arms), sponsored by Unicancer. Primary endpoint: Event-Free Survival at 3 years. Started Oct 2018; status: active, not recruiting.
02
Drugs
mifamurtide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03643133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643133.